Philips launches Verida, world’s first detector-based spectral CT powered by breakthrough AI, to advance diagnostic precision

Rhea-AI Summary

Philips (NYSE: PHG) launched Verida, described as the world’s first detector-based spectral CT fully powered by AI, announced at RSNA 2025 on November 30, 2025. Verida integrates AI across acquisition and reconstruction to deliver higher spectral and conventional image quality, claims dramatic dose reduction, up to 45% energy savings, and reconstructs 145 images/sec enabling exams to appear in <30 seconds and up to 270 exams/day. Verida is CE-marked, 510(k) pending, and availability in select markets begins in 2026.

Positive

• Reconstructs 145 images/sec
• Enables up to 270 exams/day
• Claims dramatic dose reduction with AI reconstruction
• Reports up to 45% energy savings
• CE-marked for select markets; launches in 2026

Negative

• 510(k) pending; not currently available for sale in the US
• Availability limited to select markets beginning 2026
• Energy savings estimate excludes system preparation energy

Key Figures

Peer-reviewed publications: over 800 Global installations: over 800 Energy reduction: up to 45% +5 more

8 metrics

Peer-reviewed publications over 800 Spectral CT supported by >800 peer-reviewed publications

Global installations over 800 Detector-based spectral CT global installations

Energy reduction up to 45% Verida energy consumption reduction versus reference scan

Reconstruction speed 145 images per second Verida reconstruction rate

Exam throughput up to 270 exams per day Verida capacity in high-demand settings

Patient dose reduction 80% dose reduction Basis for quoted energy savings assessment

Cancer study size 503 patients Prospective spectral body imaging study for suspected occult cancer

DAP reduction 56% DAP reduction Single-center LumiGuide study reported up to 56% DAP reduction

Market Reality Check

Price: $29.58 Vol: Volume 782,772 vs 20-day ...

normal vol

$29.58 Last Close

Volume Volume 782,772 vs 20-day average 642,234 (relative volume 1.22) suggests elevated interest ahead of this AI CT launch. normal

Technical Shares at $27.01 are trading above the 200-day MA of $25.72, and about 8.56% below the 52-week high of $29.54.

Peers on Argus

PHG gained 0.71% while key medical device peers were mixed: DXCM up 1.41%, but S...

PHG gained 0.71% while key medical device peers were mixed: DXCM up 1.41%, but STE, PODD, ZBH, and SNN all declined. The move appears more company-specific than sector-driven.

Historical Context

5 past events · Latest: Dec 04 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 04	Outlook reiteration	Positive	-4.9%	Reaffirmed 2026 outlook with expectations for growth and margin expansion.
Dec 01	AI product launch	Positive	+0.6%	Expanded LumiGuide AI 3D navigation availability in Europe and the U.S.
Nov 24	Software launch	Positive	+0.4%	Introduced web-based diagnostic viewer for fast, secure imaging access.
Nov 19	AI partnership	Positive	-1.6%	Extended Cortechs.ai partnership to embed quantitative neuroimaging in MR.
Nov 17	AI procedure support	Positive	-2.4%	Launched DeviceGuide AI device-tracking for minimally invasive valve repair.

Pattern Detected

Recent Philips news, often positive in tone, has produced mixed reactions, with several product and AI announcements followed by negative or muted price moves.

Recent Company History

Over the past few weeks, Philips has issued multiple updates tied to diagnostics and AI. On Nov 17, it introduced DeviceGuide for mitral valve repair, and on Nov 19 extended a neuroimaging partnership, both with modest share declines. A web-based diagnostic viewer launch on Nov 24 and expansion of AI navigation solution LumiGuide on Dec 1 saw small gains. However, reiterating its 2026 outlook on Dec 4 coincided with a nearly 5% drop, underscoring uneven reactions to strategic news.

Market Pulse Summary

This announcement showcases Philips’ strategy to embed AI deeply into diagnostic imaging, with Verid...

Analysis

This announcement showcases Philips’ strategy to embed AI deeply into diagnostic imaging, with Verida positioned as a detector-based spectral CT system capable of reconstructing 145 images per second and handling up to 270 exams daily. Coupled with energy savings up to 45% and extensive prior spectral CT adoption, it extends a pattern of AI-focused launches across modalities. Investors may watch how regulatory clearance, clinical adoption, and integration with existing workflows evolve.

Key Terms

spectral ct, detector-based spectral ct, pacs-native, photon-counting ct, +3 more

7 terms

spectral ct medical

"Philips pioneered detector-based spectral CT, which has been widely adopted"

Spectral CT is an advanced form of X‑ray scanning that separates the different energy “colors” of X‑rays to tell materials apart inside the body, similar to how a prism splits light into colors so you can identify substances. For investors, it matters because it can produce clearer images, reduce contrast dose or repeat scans, and enable new diagnostic capabilities, potentially driving demand for upgraded scanners and related software in hospitals and clinics.

detector-based spectral ct medical

"launch of Verida, the world’s first detector-based spectral CT fully powered by AI"

Detector-based spectral CT is an advanced type of computed tomography that uses special sensors to record the energy of individual X‑ray particles, rather than just their overall brightness. Like a prism separating light into colors, it lets clinicians distinguish different tissues and materials more clearly, often improving diagnostic accuracy and reducing radiation dose; investors care because it can drive demand for new scanners, upgrades, and higher-value imaging services.

pacs-native technical

"Philips’ spectral CT uses PACS-native delivery and has been fully embedded"

PACS-native describes medical images or records that remain in the original format and storage of a hospital’s Picture Archiving and Communication System (PACS), rather than being converted, exported, or moved into another system. For investors, PACS-native data matters because it affects how easily imaging can be accessed, shared, analyzed, or integrated with new software—think of it like knowing whether a photo stays in its camera’s original file versus being copied into a different app, which influences speed, compatibility, and cost of deploying health-tech solutions.

photon-counting ct medical

"We evaluated many systems, including photon-counting CT, but chose Philips"

Photon-counting CT is an advanced form of CT scan that detects and counts individual X-ray particles rather than measuring them as a single combined signal, producing clearer images with finer detail and better ability to tell different materials apart. For investors, it matters because the technology can improve diagnostic accuracy, reduce repeat scans and radiation exposure, and open new clinical uses—factors that can drive demand for upgraded scanners, affect hospital purchasing, and influence reimbursement and revenue for medical-imaging suppliers.

dose reduction medical

"Verida can achieve dramatic dose reduction [5] without compromising image quality"

Lowering the amount or frequency of a medication or treatment given to a patient, usually because of side effects, safety concerns, or tolerability. For investors, dose reduction matters because it can signal safety or effectiveness trade-offs that affect clinical trial results, drug labeling, prescribing patterns and ultimately sales; think of it like turning down the volume on a device to prevent distortion — it may preserve use but can change performance and demand.

ce marked regulatory

"CE marked and 510(k) pending. Not currently available for sale in the US."

CE marked indicates that a product meets European Union safety, health and environmental requirements and bears the CE symbol, acting like a safety stamp or passport that allows the product to be sold across the EU and European Economic Area. For investors, a CE mark matters because it reduces regulatory barriers and legal risk, can speed market access and revenue, and signals the company has cleared essential compliance steps for that product—affecting sales potential, costs and valuation.

510(k) regulatory

"CE marked and 510(k) pending. Not currently available for sale in the US."

A 510(k) is a U.S. regulatory submission that a medical device maker uses to show a new device is as safe and effective as an already-approved device, allowing the regulator to clear it for sale rather than requiring the longer, more stringent approval process. For investors, a cleared 510(k) usually means lower regulatory risk and a faster path to market, which can speed revenue generation and reduce uncertainty—similar to proving a new appliance works like a trusted existing model.

AI-generated analysis. Not financial advice.

November 30, 2025

• Philips pioneered detector-based spectral CT, which has been widely adopted in clinical routine exams across anatomies, supported by over 800 peer-reviewed publications [1]
• CE-marked, 510k pending Verida CT [2] integrates AI across the imaging chain, providing superb image quality while accelerating workflow and reducing dose [3, 4]

Amsterdam, the Netherlands and Chicago, USA – At RSNA 2025, Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the launch of Verida, the world’s first detector-based spectral CT fully powered by AI. This marks a transformative milestone in CT, with AI optimizing the entire imaging chain – lowering system noise, elevating image quality, and accelerating clinical workflow.

With over 800 global installations and supported by over 800 peer-reviewed publications, Philips’ spectral CT uses PACS-native delivery and has been fully embedded into clinical workflow. Spectral CT measures how tissues absorb different x-ray energy levels, enabling differentiation of materials that appear identical on conventional CT. Philips has pioneered detector-based spectral CT, delivering multiple spectral results from a single scan with no tradeoffs in performance or scan time.

Now, by integrating AI across the imaging chain, from acquisition to reconstruction, Philips Verida generates industry-leading, superior spectral image quality with minimal noise, in addition to high-definition conventional images. With its full AI capabilities, Verida can achieve dramatic dose reduction [5] without compromising image quality and reduce energy consumption by up to 45% [6].

“The clinical benefits of Verida will fundamentally change my approach to cardiac imaging,” said Prof. Eliseo Vañó Galván, cardiovascular radiologist, Chairman of the CT & MR Department at Hospital Nuestra. Sra. Del Rosario, Madrid, Spain. “With more comprehensive insights in every cardiac CT, I plan to make spectral imaging routine for all patients – building toward a fully spectral CT department. We evaluated many systems, including photon-counting CT, but chose Philips because it delivers the precision we need in a streamlined, easy-to-use platform. The result is greater diagnostic confidence and the potential to reduce the need for invasive angiograms – not just in cardiology, but across other clinical areas as well [7].”

Verida reconstructs 145 images per second, so entire exams automatically appear in less than 30 seconds – 2× faster than before and enabling up to 270 exams every day [8]. Building on Philips’ proprietary Spectral Precise Image technology – a deep learning AI reconstruction engine combined with advanced spectral imaging – and its third-generation Nano-panel Precise dual-layer detector with intrinsic noise reduction optimized for AI, Verida is designed to deliver faster, more dose-efficient spectral reconstructions. This enables clinicians to access rich spectral information from a single scan.

“Combining the latest advances in our proven spectral CT technology with AI, our flagship Verida CT system is designed to set a new standard in superior image quality and accelerated scans which are fully embedded in the radiology workflow, all to help clinicians detect and characterize disease earlier, reduce variability in diagnoses, and support efficient treatment pathways – in a single scan,” said Dan Xu, Business Leader of CT at Philips. “While photon-counting CT adds complexity, is yet to move from the research arena into clinical practice, Philips spectral CT has been a clinical workhorse for more than a decade and delivers comparable or better clinical outcomes, standing up to the most demanding throughput and at significantly lower total cost of ownership”.

Verida extends Philips’ software-defined CT approach, pairing AI-driven spectral precision to advance both clinical and operational outcomes. Built for high-demand environments, it streamlines workflows, reduces repeat scans, and delivers consistently sharp imaging across all care pathways.

Philips is debuting Verida at RSNA 2025, with availability in select markets beginning in 2026 [9].

[1] Data on file. 
[2] CE marked and 510(k) pending. Not currently available for sale in the US.
[3] Andersen MB et al. Impact of spectral body imaging in patients suspected for occult cancer: a prospective study of 503 patients. Eur Radiol2020. doi.org/10.1007/s00330-020-06878-7
[4] Andersen MB et al. Economic impact of spectral body imaging in the diagnosis of patients suspected of occult cancer. Insights into Imaging 2021. doi.org/10.1186/s13244-021-01116-0. Results of customer testimonies are not predictive of results in other cases, where results may vary.
[5] Dose reduction assessments were performed using reference body protocol. In clinical practice, the use of Spectral Precise Image may reduce CT patient dose depending on the clinical task, patient size, and anatomical location. A consultation with a radiologist and a physicist should be made to determine the appropriate dose to obtain diagnostic image quality for the particular clinical task.
[6] Based on Axial Body 3D Scan with 80% dose reduction. Energy savings for system preparation is not included.
[7] Spectral CT Verida Premium up to 270 (4 CIRS config) exams a day (16 hours dual shift working day) meeting the needs of radiology departments with extended work hours and very high patient throughput.
[8] The statements of the clinician reflect independent opinion and are not intended to imply product performance prior to regulatory clearance.
[9] Pending regulatory clearance.

For further information, please contact:

Anna Hogrebe
Philips Global External Relations
Tel.: +1 416 270 6757
E-mail: anna.hogrebe@philips.com

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home.

Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2024 sales of EUR 18 billion and employs approximately 67,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Attachments

• Philips Verida spectral CT system, angle view
• Philips Verida spectral CT system, straight-on view

FAQ

What is Philips Verida CT and when was it announced (PHG)?

Verida is a detector-based spectral CT fully powered by AI, announced on November 30, 2025.

How fast does Philips (PHG) say Verida reconstructs CT images?

Philips reports Verida reconstructs at 145 images per second, with exams appearing in <30 seconds.

What dose and energy claims did Philips make for Verida (PHG)?

Philips claims Verida can achieve dramatic dose reduction and reduce energy consumption by up to 45%.

Is the Philips Verida CT available for sale in the US (PHG)?

No; Verida is CE-marked with a 510(k) pending and is not currently available for sale in the US.

When will Verida CT be available and in which markets (PHG)?

Philips expects availability in select markets beginning in 2026, pending regulatory clearance.

What throughput benefit does Philips (PHG) claim Verida provides to radiology departments?

Philips states Verida can support workflows of up to 270 exams per day in high-demand settings.